White Papers
Benefit from Ecraid's Large Expertise Infrastructure for Efficient and High-quality ID research
Efficiency and quality in trials should never be a trade-off. Ecraid is the premier European academic network for infectious diseases and AMR, comprising over 1,200 clinical sites across 42 countries.
Step into the Future of ID Clinical Research alongside Ecraid
Traditional clinical trials are often too slow to respond to fast-moving infectious threats. Ecraid is changing that.
Better, faster small-molecule synthesis: leveraging modern tools to evaluate and optimize process chemistry
Better, faster small-molecule synthesis: leveraging modern tools to evaluate and optimize process chemistry
Precision in miniature: optimizing multiparticulate formulations for pediatric oncology
This white paper details a collaborative effort between Lonza’s Bend, OR site and Pfizer’s Groton, CT team to develop a robust commercial control strategy for a pediatric dosage form for crizotinib (Xalkori) in a material sparing fashion.
Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates
Bioconjugates are no longer just for cancer therapies. This paper reveals how innovative advancements are opening up a new world of possibilities, from muscle disorders to inflammatory diseases.
ULTRUS ComplianceWire 2024 Benchmarking Study - Trends in Auditing and Supplier Management
Every year, UL Solutions conducts an anonymous benchmarking survey across its roughly 600 ULTRUS ComplianceWire customers, most of whom operate in the pharmaceutical and medical device sectors.
Unlock Faster, More Confident Biosimilar Development
Developing biosimilars requires rigorous analytical characterization to ensure safety, efficacy, and regulatory approval.
Master Measurement Uncertainty in Laboratory Weighing
Every laboratory measurement carries some level of uncertainty—but in regulated environments, uncontrolled variation can compromise compliance, data integrity, and research outcomes.
Protect Your Pharma Supply Chain from Global Disruptions
In today’s unpredictable world, pharmaceutical supply chains face growing risks—from geopolitical tensions and regulatory shifts to raw material shortages and natural disasters.
Sterile Formulation Strategies to Shorten Timelines for First-in-Human Studies
On the long and costly path to market, early development decisions that prepare a molecule for its clinical journey are among the most critical. Creating a complex formulation from the outset can introduce challenges and bottlenecks, potentially slowing your progress in later phases. Conversely, moving too quickly without gathering sufficient data can make it difficult to expedite timelines.
